Skip to content
Checking whether you are signed in

Pfizer Inc.

PFENew York Stock ExchangeFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 7, 2026, 10:41 PM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

Pfizer sells prescription medicines and vaccines, and about a quarter of its revenue comes from four drugs (Eliquis, Ibrance, Xtandi and Xeljanz) that lose US exclusivity or face Medicare negotiated prices between 2026 and 2028. In the third quarter of fiscal 2026 revenue was flat at $16.6 billion, but grew 7.3% outside the COVID products, and Pfizer raised its full-year guidance; half of that growth, however, came from a price gain on Eliquis, whose US generics may launch from April 2028. Moatsight estimates revenue of $60.1 billion and free cash flow of $10.9 billion over the next four quarters, and estimates that free cash flow will fall below the dividend in 2028 and 2029. Whether newer products such as Padcev, the Vyndaqel family and the obesity program acquired with Metsera can fill the gap after 2028 is the question that decides the company's value.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers